CX-904
Advanced Solid Tumors (EGFRxCD3 T-cell engager)
Key Facts
Indication
Advanced Solid Tumors (EGFRxCD3 T-cell engager)
Phase
Phase 1
Status
Active
Company
About CytomX Therapeutics
CytomX Therapeutics is developing a new class of targeted cancer therapies using its Probody platform, which aims to enhance the therapeutic window of antibody-based drugs by restricting their activity to diseased tissue. The company has advanced multiple candidates into clinical development, including its lead asset praluzatamab ravtansine (CX-2009), and has established high-value collaborations with industry leaders like AbbVie, Amgen, Astellas, and Bristol Myers Squibb. As a publicly traded company, CytomX is focused on leveraging its platform to address significant unmet needs in oncology while managing its capital to advance key programs.
View full company profile